HIGH-DOSE NALOXONE FORMULATION

The USPTO published a patent application for high-dose Naloxone formulations intended to treat overdose from ultra-potent synthetic opioids. The formulation includes naloxone hydrochloride or a pharmaceutically acceptable salt, one or more preservatives, buffering agents, a tonicity modifier, and optionally a pH modifier. The application (US20260091030A1) names inventors Gita Shankar and Suresh Potharaju, with filing date September 1, 2023. CPC classifications indicate applications in opioid antagonist compositions (A61K 31/485) and pharmaceutical preparations (A61K 9/0019, A61K 9/08).

Pharmaceutical companies and drug manufacturers developing opioid overdose treatments should review this application to understand potential intellectual property landscape implications for naloxone-based products. While patent applications do not create immediate compliance obligations, companies should assess whether this IP development could affect future product strategies or existing formulations. This is a draft application pending examination—granted patents would create enforceable IP rights in the pharmaceutical manufacturing space.